<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OTO</journal-id>
<journal-id journal-id-type="hwp">spoto</journal-id>
<journal-title>Otolaryngology–Head and Neck Surgery</journal-title>
<issn pub-type="ppub">0194-5998</issn>
<issn pub-type="epub">1097-6817</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0194599812457557</article-id>
<article-id pub-id-type="publisher-id">10.1177_0194599812457557</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Evidence-Based Critical Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Insufficient Evidence for the Effect of Corticosteroid Treatment on Recovery of Vestibular Neuritis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wegner</surname><given-names>Inge</given-names></name>
<xref ref-type="aff" rid="aff1-0194599812457557">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>van Benthem</surname><given-names>Peter Paul G.</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff2-0194599812457557">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Aarts</surname><given-names>Mark C. J.</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0194599812457557">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bruintjes</surname><given-names>Tjasse D.</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff2-0194599812457557">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Grolman</surname><given-names>Wilko</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0194599812457557">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>van der Heijden</surname><given-names>Geert J. M. G.</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff3-0194599812457557">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0194599812457557"><label>1</label>Department of Otorhinolaryngology, University Medical Centre Utrecht, Utrecht, the Netherlands</aff>
<aff id="aff2-0194599812457557"><label>2</label>Gelre Hospitals, Apeldoorn, the Netherlands</aff>
<aff id="aff3-0194599812457557"><label>3</label>Julius Centre for Health Sciences and Primary Care, Utrecht, the Netherlands</aff>
<author-notes>
<corresp id="corresp1-0194599812457557">Inge Wegner, Department of Otolaryngology, University Medical Centre Utrecht, PO Box 85500, 3508 GA Utrecht, the Netherlands Email: <email>ENT-research@umcutrecht.nl</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>11</month>
<year>2012</year>
</pub-date>
<volume>147</volume>
<issue>5</issue>
<fpage>826</fpage>
<lpage>831</lpage>
<history>
<date date-type="received">
<day>13</day>
<month>7</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>7</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© American Academy of Otolaryngology—Head and Neck Surgery Foundation 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Official journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation</copyright-holder>
</permissions>
<abstract>
<p>The authors studied the effect of corticosteroid treatment on clinical recovery and recovery of vestibular function in patients with vestibular neuritis. The comprehensive search (March 29, 2012) yielded 496 original papers, of which 5 (including 199 patients) during full-text screening satisfied our eligibility criteria. Methods assessment showed that 1 study (30 patients) provided direct evidence and carried low risk of bias. Two studies properly reported on their random and concealed allocation of treatment. In 1 study, patients were not randomly allocated to treatment. Blinding of outcomes was lacking in 2 studies, whereas outcome data were clearly incomplete for 2 studies. Given the wide variety in outcome measures and scales and follow-up duration, the meaning of the size of reported effects is not clear. Therefore, the reported effects cannot simply be compared between studies, and this precludes pooling of study results. Still, there are large differences between studies in the size of the reported absolute effects after the placebo treatment. Moreover, the difference in effects between treatments is rather small and does not always favor corticosteroids. The moderate to high risk of bias of studies precludes firm conclusions, whereas the reported short-term effects on symptom recovery and improvement of peripheral vestibular function are too small to be clinically important. No long-term effect on symptom recovery has been shown. Recommendations or decisions for corticosteroid treatment in patients with vestibular neuritis cannot be based on current best evidence and therefore should be discussed with the patient.</p>
</abstract>
<kwd-group>
<kwd>vestibular neuritis</kwd>
<kwd>corticosteroids</kwd>
<kwd>clinical recovery</kwd>
<kwd>vestibular function recovery</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0194599812457557">
<title>Clinical Question</title>
<p>A 45-year-old woman is referred with a rapid onset of severe vertigo, which is associated with nausea and vomiting. She has no auditory symptoms such as hearing loss and tinnitus, neurologic symptoms are absent, and neuro-otologic examination shows a horizontal-rotatory spontaneous nystagmus toward the unaffected ear. The diagnosis of vestibular neuritis is made. You consider treating the patient with corticosteroids but wonder what the short- and long-term effects of this treatment are. During discussion with your colleagues, you decide to pursue the answer for the following clinical question: what is the effect of corticosteroid treatment, compared with placebo, on clinical recovery (vertigo and nausea) and recovery of vestibular function (caloric paresis) in patients with vestibular neuritis?</p>
</sec>
<sec id="section2-0194599812457557" sec-type="methods">
<title>Methods</title>
<p>We conducted a systematic search in PubMed, Embase, the Cochrane Library, CINAHL, and Scopus using synonyms for vestibular neuritis and corticosteroid treatment (<xref ref-type="table" rid="table1-0194599812457557"><bold>Table 1</bold></xref>). Title and abstract of the retrieved records were screened for inclusion, and duplicates were excluded. We included records reporting original study data on the effect of corticosteroid treatment for patients with vestibular neuritis (see <xref ref-type="fig" rid="fig1-0194599812457557"><bold>Figure 1</bold></xref> for selection criteria). During full-text screening, inclusion was restricted to studies that confirmed the diagnosis of vestibular neuritis by 3 criteria: (1) a history of acute onset of vertigo, nausea, and postural imbalance; (2) a horizontal spontaneous nystagmus with a rotational component to the unaffected ear; and (3) hyporesponsiveness of the affected ear at electronystagmography (ENG), with caloric lateralization of more than 25%. For final inclusion, corticosteroid treatment had to start within 3 days after symptom onset. Systematic reviews, opinion articles, animal studies, case reports, and non-English-language or non-Dutch-language studies were excluded.</p>
<table-wrap id="table1-0194599812457557" position="float">
<label>Table 1.</label>
<caption><p>Search for Studies on the Effect of Corticosteroid Treatment for Patients with Vestibular Neuritis (Date of Search: March 29, 2012)</p></caption>
<graphic alternate-form-of="table1-0194599812457557" xlink:href="10.1177_0194599812457557-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Database</th>
<th align="center">Search</th>
<th align="center">Field</th>
</tr>
</thead>
<tbody>
<tr>
<td>PubMed Cochrane Library CINAHL Scopus</td>
<td>(vestibular AND (neuritis OR neuronitis OR neuropathy OR vertigo) OR vestibulopathy OR (“acute vestibular” AND (dysfunction OR dysfunctions OR disfunction OR disfunctions OR disorder OR disorders)) OR labyrinthitis OR neurolabyrinthitis) AND (steroid OR steroids OR corticosteroid OR corticosteroids OR glucocorticoid OR glucocorticoids OR prednisone OR prednisolone OR methylprednisone OR methylprednisolone OR dexamethasone)</td>
<td>Title/abstract</td>
</tr>
<tr>
<td>Embase</td>
<td>(vestibular:ab,ti AND (neuritis:ab,ti OR neuronitis:ab,ti OR neuropathy:ab,ti OR vertigo:ab,ti) OR vestibulopathy:ab,ti OR (“acute vestibular”:ab,ti AND (dysfunction:ab,ti OR dysfunctions:ab,ti OR disfunction:ab,ti OR disfunctions:ab,ti OR disorder:ab,ti OR disorders:ab,ti)) OR labyrinthitis:ab,ti OR neurolabyrinthitis:ab,ti) AND (steroid:ab,ti OR steroids:ab,ti OR corticosteroid:ab,ti OR corticosteroids:ab,ti OR glucocorticoid:ab,ti OR glucocorticoids:ab,ti OR prednisone:ab,ti OR prednisolone:ab,ti OR methylprednisone:ab,ti OR methylprednisolone:ab,ti OR dexamethasone:ab,ti)</td>
<td/>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="fig1-0194599812457557" position="float">
<label>Figure 1.</label>
<caption><p>Flowchart for selection of studies on the effect of corticosteroid treatment for patients with vestibular neuritis.</p></caption>
<graphic xlink:href="10.1177_0194599812457557-fig1.tif"/>
</fig>
<p>Related publications were searched in PubMed, whereas Scopus and Web of Science were used for cross-reference checking for studies not identified by our initial literature search.</p>
<p>We used predefined criteria (<xref ref-type="table" rid="table2-0194599812457557"><bold>Table 2</bold></xref>) for assessing the directness of evidence and risk of bias of all selected articles. The presented results of this assessment are based on full agreement after consensus discussion about initial discrepancies. All studies with either or both low directness of evidence and high risk of bias were excluded for further review. Outcome data of included studies were extracted or (re)calculated using comprehensive meta-analysis.<sup><xref ref-type="bibr" rid="bibr1-0194599812457557">1</xref></sup></p>
<table-wrap id="table2-0194599812457557" position="float">
<label>Table 2.</label>
<caption><p>Study Assessment of Studies on the Effect of Corticosteroid Treatment for Patients with Vestibular Neuritis</p></caption>
<graphic alternate-form-of="table2-0194599812457557" xlink:href="10.1177_0194599812457557-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th/>
<th align="center" colspan="3">Directness of Evidence<hr/></th>
<th align="center" colspan="6">Risk of Bias<hr/></th>
</tr>
<tr>
<th align="left">Study (PubMed ID)</th>
<th align="center">Sample Size of Study</th>
<th align="center">Study Design</th>
<th align="center">Patients</th>
<th align="center">Treatment</th>
<th align="center">Outcome</th>
<th align="center">Treatment Allocation</th>
<th align="center">Blinding (S)</th>
<th align="center">Blinding (C)</th>
<th align="center">Standardization</th>
<th align="center">Complete Data (S)</th>
<th align="center">Complete Data (C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shupak (18317392)<sup><xref ref-type="bibr" rid="bibr2-0194599812457557">2</xref></sup></td>
<td>30</td>
<td>RCT</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>○</td>
<td>○</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Ariyasu (2187486)<sup><xref ref-type="bibr" rid="bibr3-0194599812457557">3</xref></sup></td>
<td>20</td>
<td>RCT</td>
<td>●</td>
<td>○</td>
<td>●</td>
<td>○</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Rezaie (no PMID)<sup><xref ref-type="bibr" rid="bibr4-0194599812457557">4</xref></sup></td>
<td>40</td>
<td>RCT</td>
<td>●</td>
<td>●</td>
<td>○</td>
<td>○</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Strupp (15269315)<sup><xref ref-type="bibr" rid="bibr5-0194599812457557">5</xref></sup></td>
<td>73</td>
<td>RCT</td>
<td>●</td>
<td>●</td>
<td>○</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>Kitahara (12739240)<sup><xref ref-type="bibr" rid="bibr6-0194599812457557">6</xref></sup></td>
<td>36</td>
<td>PCC</td>
<td>●</td>
<td>○</td>
<td>●</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>●</td>
<td>○</td>
<td>●</td>
</tr>
<tr>
<td>Ohbayashi (8470496)<sup><xref ref-type="bibr" rid="bibr7-0194599812457557">7</xref></sup></td>
<td>111</td>
<td>R/PCC</td>
<td>●</td>
<td>●</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>●</td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>Karlberg (21817947)<sup><xref ref-type="bibr" rid="bibr8-0194599812457557">8</xref></sup></td>
<td>74/100<sup><xref ref-type="table-fn" rid="table-fn9-0194599812457557">a</xref></sup></td>
<td>PCC</td>
<td>●</td>
<td>●</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>●</td>
<td>?</td>
<td>?</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0194599812457557">
<p><italic>Study Design</italic>: PCC, prospective case-control study; RCT, randomized controlled trial; R/PCC, case-control study (unclear whether retrospective or prospective).</p>
</fn>
<fn id="table-fn2-0194599812457557">
<p><italic>Directness of Evidence</italic>:</p>
</fn>
<fn id="table-fn3-0194599812457557">
<p>Patients: vestibular neuritis as determined by clinical signs and symptoms and caloric testing: ● = yes; ○ = no. Treatment: ● = corticosteroids administered within 3 days after onset of symptoms; ○ = corticosteroids in combination with antiviral agents, administered more than 3 days after onset of symptoms, other. Outcome: ● = recovery measured by clinical signs and caloric testing; ○ = recovery measured by clinical signs only or caloric testing only, other.</p>
</fn>
<fn id="table-fn4-0194599812457557">
<p><italic>Risk of Bias</italic>:</p>
</fn>
<fn id="table-fn5-0194599812457557">
<p>Treatment allocation: ● = randomized or concealed; ○ = neither randomization nor concealment; ? = unclear, no information provided.</p>
</fn>
<fn id="table-fn6-0194599812457557">
<p>Blinding (S) of treatment nature during measurement of clinical signs and symptoms and blinding (C) of treatment nature during caloric testing: ● = patients and clinicians blinded; ○ = only patients blinded or no blinding ? = unclear, no information provided.</p>
</fn>
<fn id="table-fn7-0194599812457557">
<p>Standardization treatment regimen: ● = yes; ○ = no; ? = unclear, no information provided.</p>
</fn>
<fn id="table-fn8-0194599812457557">
<p>Completeness of outcome data (S) for clinical signs and symptoms and completeness of outcome data (C) for caloric testing: ● = below 10% missing data; ○ = 10% or more missing data; ? = unclear, no information provided.</p>
</fn>
<fn id="table-fn9-0194599812457557">
<label>a</label>
<p>Two different control groups used of n = 41 (outcome measure vestibular paresis) and n = 67 (outcome measure clinical recovery).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section3-0194599812457557" sec-type="results">
<title>Results</title>
<sec id="section4-0194599812457557">
<title>Retrieval and selection</title>
<p>We retrieved 496 titles, of which 220 were identified as unique studies (<xref ref-type="fig" rid="fig1-0194599812457557"><bold>Figure 1</bold></xref>; date of last search was March 29, 2012). After selection based on title and abstract, as well as subsequent full-text screening, 7 articles were considered eligible for answering our question.<sup><xref ref-type="bibr" rid="bibr2-0194599812457557">2</xref><xref ref-type="bibr" rid="bibr3-0194599812457557"/><xref ref-type="bibr" rid="bibr4-0194599812457557"/><xref ref-type="bibr" rid="bibr5-0194599812457557"/><xref ref-type="bibr" rid="bibr6-0194599812457557"/><xref ref-type="bibr" rid="bibr7-0194599812457557"/>-<xref ref-type="bibr" rid="bibr8-0194599812457557">8</xref></sup> Two articles not published in English or Dutch as full text were excluded.<sup><xref ref-type="bibr" rid="bibr9-0194599812457557">9</xref>,<xref ref-type="bibr" rid="bibr10-0194599812457557">10</xref></sup> Cross-reference checking revealed no additional articles. The 5 placebo-controlled studies selected in total included 199 patients.</p>
<p>Assessment of their reported methods (<xref ref-type="table" rid="table2-0194599812457557"><bold>Table 2</bold></xref>) showed that only 1 study<sup><xref ref-type="bibr" rid="bibr2-0194599812457557">2</xref></sup> provided direct evidence (highest relevance) and carried a low risk of bias (highest validity). Therefore, we put most trust in this study.</p>
</sec>
<sec id="section5-0194599812457557">
<title>Directness of evidence</title>
<p>Important limitations in the directness of evidence were found in 4 other studies—notably, uncertainty when corticosteroid treatment was started,<sup><xref ref-type="bibr" rid="bibr3-0194599812457557">3</xref></sup> late start of corticosteroid treatment (3 instead of 5 days after symptom onset),<sup><xref ref-type="bibr" rid="bibr6-0194599812457557">6</xref></sup> no reporting outcome data for recovery of clinical signs and symptoms,<sup><xref ref-type="bibr" rid="bibr4-0194599812457557">4</xref></sup> or peripheral vestibular recovery.<sup><xref ref-type="bibr" rid="bibr5-0194599812457557">5</xref></sup> We, however, decided to include these 4 studies for further analyses.</p>
</sec>
<sec id="section6-0194599812457557">
<title>Risk of bias</title>
<p>Only 2 studies (together 103 patients)<sup><xref ref-type="bibr" rid="bibr2-0194599812457557">2</xref>,<xref ref-type="bibr" rid="bibr5-0194599812457557">5</xref></sup> properly reported on their random and concealed allocation of treatment. In 1 study, patients (n = 36) were not randomly allocated to treatment.<sup><xref ref-type="bibr" rid="bibr6-0194599812457557">6</xref></sup> Blinding of outcomes was adequate in 3 studies,<sup><xref ref-type="bibr" rid="bibr3-0194599812457557">3</xref><xref ref-type="bibr" rid="bibr4-0194599812457557"/>-<xref ref-type="bibr" rid="bibr5-0194599812457557">5</xref></sup> whereas outcome data were clearly incomplete for 2 studies.<sup><xref ref-type="bibr" rid="bibr5-0194599812457557">5</xref>,<xref ref-type="bibr" rid="bibr6-0194599812457557">6</xref></sup> Ariyasu et al<sup><xref ref-type="bibr" rid="bibr3-0194599812457557">3</xref></sup> used a crossover design: if no significant reduction of vertigo occurred within the first 24 hours of treatment, patients were allowed to switch medications blindly. We considered the risk of bias of the case-control studies by Ohbayashi et al<sup><xref ref-type="bibr" rid="bibr7-0194599812457557">7</xref></sup> and by Karlberg and Magnusson<sup><xref ref-type="bibr" rid="bibr8-0194599812457557">8</xref></sup> too high to include them for further review.</p>
</sec>
<sec id="section7-0194599812457557">
<title>Data extraction</title>
<p>The included studies are described in <xref ref-type="table" rid="table3-0194599812457557"><bold>Tables 3</bold></xref><xref ref-type="table" rid="table4-0194599812457557"/> to <xref ref-type="table" rid="table5-0194599812457557"><bold>5</bold></xref>. These tables also show the outcome data of the included studies. There are major dissimilarities between studies regarding dosing of corticosteroid treatment, follow-up duration, and outcome measures and scales. There is little information on the baseline risk of patients, but there are large differences between studies in the size of the reported absolute effects after the placebo treatment. The difference in effects between treatments is rather small and does not always favor corticosteroids.</p>
<table-wrap id="table3-0194599812457557" position="float">
<label>Table 3.</label>
<caption><p>Study Descriptives of Studies on the Effect of Corticosteroid Treatment for Patients with Vestibular Neuritis</p></caption>
<graphic alternate-form-of="table3-0194599812457557" xlink:href="10.1177_0194599812457557-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th/>
<th align="center" colspan="3">Comedication<hr/></th>
</tr>
<tr>
<th align="left">Study</th>
<th align="center">Corticosteroid Treatment</th>
<th align="center">Placebo Treatment</th>
<th align="center">Type, Dosing, and Duration</th>
<th align="center">Delivery Route</th>
<th align="center">Standardized</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shupak et al (2008)<sup><xref ref-type="bibr" rid="bibr2-0194599812457557">2</xref></sup></td>
<td>n = 15<break/>Prednisone 1 mg/kg/d, 5 d, tapering down 15 d</td>
<td>n = 15</td>
<td>Famotidine 20 mg/d, 5 d<sup><xref ref-type="table-fn" rid="table-fn11-0194599812457557">a</xref></sup><break/>Promathazine 75 mg/d or cinnarizine AN 5 d</td>
<td>Oral</td>
<td>No<sup><xref ref-type="table-fn" rid="table-fn11-0194599812457557">a</xref></sup></td>
</tr>
<tr>
<td>Ariyasu et al (1990)<sup><xref ref-type="bibr" rid="bibr3-0194599812457557">3</xref></sup></td>
<td>n = 10<break/>Prednisone 23 mg/d, 1 d, tapering down 7 d</td>
<td>n = 10</td>
<td>None</td>
<td/>
<td/>
</tr>
<tr>
<td>Rezaie et al (2006)<sup><xref ref-type="bibr" rid="bibr4-0194599812457557">4</xref></sup></td>
<td>n = 20<break/>Dexamethasone 6 mg thrice daily, 3 d</td>
<td>n = 20</td>
<td>Dimenhydrinate 50 mg/d, 3 d</td>
<td>Oral</td>
<td>Yes</td>
</tr>
<tr>
<td>Strupp et al (2004)<sup><xref ref-type="bibr" rid="bibr5-0194599812457557">5</xref></sup></td>
<td>n = 35<break/>Prednisone 100 mg/d, 3 d, tapering down 19 d</td>
<td>n = 38</td>
<td>Pirenzepine 150 mg/d Dimenhydrinate 50-150 mg/d AN 3 d</td>
<td>Oral</td>
<td>Yes</td>
</tr>
<tr>
<td>Kitahara et al (2003)<sup><xref ref-type="bibr" rid="bibr6-0194599812457557">6</xref></sup></td>
<td>n = 5<break/>Prednisone 500 mg/d IV, 1 d, tapering down 7 d</td>
<td>n = 8</td>
<td>Vitamin B<sub>12</sub>, anti–gastric ulcer drugs and antiemetics; exact type, dosing, and duration unknown</td>
<td>Intravenously</td>
<td>Yes</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn10-0194599812457557">
<p>Abbreviations: AN, as needed; IV, intravenous.</p>
</fn>
<fn id="table-fn11-0194599812457557">
<label>a</label>
<p>Famotidine was administered to patients in the treatment group only.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table4-0194599812457557" position="float">
<label>Table 4.</label>
<caption><p>Studies on the Effect of Corticosteroid Treatment for Patients with Vestibular Neuritis with Outcomes for Clinical Signs and Symptoms</p></caption>
<graphic alternate-form-of="table4-0194599812457557" xlink:href="10.1177_0194599812457557-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Study</th>
<th align="center">Corticosteroid Treatment</th>
<th align="center">Placebo Treatment</th>
<th align="center">Outcome Scale</th>
<th align="center">Follow-up Duration</th>
<th align="center">Outcome Measure</th>
<th align="center">Outcome Data Corticosteroid</th>
<th align="center">Outcome Data Placebo</th>
<th align="center">Difference between Groups (95% CI)<sup><xref ref-type="table-fn" rid="table-fn13-0194599812457557">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>Shupak et al (2008)<sup><xref ref-type="bibr" rid="bibr2-0194599812457557">2</xref></sup></td>
<td>n = 15<break/>Prednisone 1 mg/kg/d, 5 d, tapering down 15 d</td>
<td>n = 15</td>
<td>Dizziness Handicap Inventory<sup><xref ref-type="table-fn" rid="table-fn14-0194599812457557">b</xref></sup></td>
<td>1 mo<break/>3 mo<break/>6 mo<break/>12 mo</td>
<td>Dizziness</td>
<td>20.9 (21.7)<break/>14.8 (19)<break/>17.8 (14.4)<break/>11.1 (14.2)</td>
<td>15.8 (12.3<break/>6.5 (6.8)<break/>8.3 (7.8)<break/>8.1 (12.6)</td>
<td>−5.1 (−17.7 to 7.5)<break/>−8.3 (−18.5 to 1.9)<break/>−9.5 (−17.8 to −1.2)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup><break/>−3.0 (−12.6 to 6.6)</td>
</tr>
<tr>
<td>Ariyasu et al (1990)<sup><xref ref-type="bibr" rid="bibr3-0194599812457557">3</xref></sup></td>
<td>n = 10<break/>Prednisone 23 mg/d, 1 d, tapering down 7 d</td>
<td>n = 10</td>
<td>Subjective relieve of vertigo</td>
<td>1 mo</td>
<td>Vertigo</td>
<td>90%<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup></td>
<td>30%<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup></td>
<td/>
</tr>
<tr>
<td>Rezaie et al (2006)<sup><xref ref-type="bibr" rid="bibr4-0194599812457557">4</xref></sup></td>
<td>n = 20<break/>Dexamethasone 6 mg thrice daily, 3 d</td>
<td>n = 20</td>
<td>Mean time for symptom relief in hours</td>
<td/>
<td>Vertigo<break/>Nausea<break/>Nystagmus</td>
<td>45.6 (15.3)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup><break/>28.8 (12.5)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup><break/>28.8 (9.8)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup></td>
<td>68.4 (11.7)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup><break/>54 (20.4)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup><break/>63.6 (16.1)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup></td>
<td>22.8 (14.4 to 31.2)<break/>25.2 (14.7 to 35.7)<break/>34.8 (26.5 to 43.1)</td>
</tr>
<tr>
<td>Kitahara et al (2003)<sup><xref ref-type="bibr" rid="bibr6-0194599812457557">6</xref></sup></td>
<td>n = 5<break/>Prednisone 500 mg/d IV, 1 d, tapering down 7 d</td>
<td>n = 8</td>
<td>Dizziness and Unsteadiness Questionnaire<sup><xref ref-type="table-fn" rid="table-fn16-0194599812457557">d</xref></sup></td>
<td>1 wk</td>
<td>Limitation of social activity<break/>Aggravating body movements<break/>Limitation of body activity</td>
<td>14.60 (0.40)<break/>14.20 (0.37)<break/>14.40 (0.40)</td>
<td>12.50 (1.05)<break/>12.38 (0.65)<break/>12.50 (0.71)</td>
<td>−2.10 (−3.07 to −1.12)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup><break/>−1.82 (−2.45 to −1.18)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup><break/>−1.90 (−2.59 to −1.21)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup></td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>Mood disturbance</td>
<td>6.80 (0.92)</td>
<td>7.13 (0.81)</td>
<td>0.33 (−0.62 to 1.28)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>Interperson relationships</td>
<td>12.60 (0.98)</td>
<td>12.63 (0.73)</td>
<td>0.03 (−0.90 to 0.96)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>24 mo</td>
<td>Limitation of social activity</td>
<td>4.20 (0.20)</td>
<td>4.75 (0.16)</td>
<td>0.55 (0.35 to 0.75)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup></td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>Aggravating body movements</td>
<td>5.00 (0.32)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup></td>
<td>6.25 (0.31)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup></td>
<td>1.25 (0.90 to 1.60)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup></td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>Limitation of body activity</td>
<td>4.80 (0.49)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup></td>
<td>7.13 (0.55)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup></td>
<td>2.33 (1.73 to 2.92)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup></td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>Mood disturbance</td>
<td>3.60 (0.25)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup></td>
<td>4.50 (0.27)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup></td>
<td>0.90 (0.61 to 1.19)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup></td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>Interperson relationships</td>
<td>3.40 (0.25)</td>
<td>3.86 (0.30)</td>
<td>0.46 (0.14 to 0.78)<sup><xref ref-type="table-fn" rid="table-fn15-0194599812457557">c</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn12-0194599812457557">
<p>Unless otherwise indicated, the included data are presented as mean (SD). Abbreviations: CI, confidence interval; IV, intravenous.</p>
</fn>
<fn id="table-fn13-0194599812457557">
<label>a</label>
<p>When between-group difference is positive, this favors corticosteroid or placebo.</p>
</fn>
<fn id="table-fn14-0194599812457557">
<label>b</label>
<p>Shupak et al<sup><xref ref-type="bibr" rid="bibr2-0194599812457557">2</xref></sup> used the Dizziness Handicap Inventory (DHI)<sup><xref ref-type="bibr" rid="bibr12-0194599812457557">12</xref></sup> to assess the effects of vestibular impairment on daily functioning and mood. The questionnaire is composed of 25 questions pertaining to the functional, physical, and emotional impact of dizziness. A maximum score of 4 can be assigned to each question. A score of 16 to 34 points is considered a mild handicap, a score of 36 to 52 points a moderate handicap, and a score of 54 points or more a severe handicap. Shupak et al considered a score of 6 points or less to be normal.</p>
</fn>
<fn id="table-fn15-0194599812457557">
<label>c</label>
<p><italic>P</italic> &lt; .05.</p>
</fn>
<fn id="table-fn16-0194599812457557">
<label>d</label>
<p>Kitahara et al<sup><xref ref-type="bibr" rid="bibr6-0194599812457557">6</xref></sup> used the Dizziness and Unsteadiness Questionnaire,<sup><xref ref-type="bibr" rid="bibr13-0194599812457557">13</xref></sup> which consists of 14 items. The answers were scored with a maximum of 5 points. Scores were collected according to classification to 1 of 5 factors (handicap of social activity by dizziness, body movements aggravating dizziness, limitation of body activity, disturbance of mood, and handicap of interperson relationship due to dizziness) with a maximum score of 15 points per factor.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table5-0194599812457557" position="float">
<label>Table 5.</label>
<caption><p>Studies on the Effect of Corticosteroid Treatment for Patients with Vestibular Neuritis with Outcomes for Caloric Test Results<sup><xref ref-type="table-fn" rid="table-fn18-0194599812457557">a</xref></sup></p></caption>
<graphic alternate-form-of="table5-0194599812457557" xlink:href="10.1177_0194599812457557-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">Compared Treatments<hr/></th>
<th align="center">Follow-up<hr/></th>
<th align="center" colspan="2">Caloric Test at Presentation<hr/></th>
<th align="center" colspan="2">Caloric Test at Follow-up<hr/></th>
<th/>
<th align="center" colspan="2">Normal Caloric Test, %<hr/></th>
</tr>
<tr>
<th align="center">Study</th>
<th align="center">Cortico-steroid</th>
<th align="center">Placebo</th>
<th align="center">Duration</th>
<th align="center">Cortico-steroid</th>
<th align="center">Placebo</th>
<th align="center">Cortico-steroid</th>
<th align="center">Placebo</th>
<th align="center">Difference between Groups (95% CI)<sup><xref ref-type="table-fn" rid="table-fn19-0194599812457557">b</xref></sup></th>
<th align="center">Cortico-steroid</th>
<th align="center">Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shupak et al (2008)<sup><xref ref-type="bibr" rid="bibr2-0194599812457557">2</xref></sup></td>
<td>n = 15<break/>Prednisone 1 mg/kg/d, 5 d, tapering down 15 d</td>
<td>n = 15</td>
<td>1 mo<break/>3 mo<break/>6 mo<break/>12 mo</td>
<td>59 (27)<break/>59 (27)<break/>59 (27)<break/>59 (27)</td>
<td>58 (30)<break/>58 (30)<break/>58 (30)<break/>58 (30)</td>
<td>35.6 (29)<break/>30.3 (20.4)<break/>22.7 (15)<break/>25.6 (26.3)</td>
<td>44.2 (33.3)<break/>44.5 (35.4)<break/>29.6 (35.7)<break/>12 (7.7)</td>
<td>8.6 (−13.7 to 30.9)<break/>14.2 (−6.5 to 34.9)<break/>6.9 (−12.7 to 26.5)<break/>−13.6 (−27.5 to 0.3)</td>
<td>60<sup><xref ref-type="table-fn" rid="table-fn19-0194599812457557">c</xref></sup><break/> 73<sup><xref ref-type="table-fn" rid="table-fn19-0194599812457557">c</xref></sup><break/>73 <break/>73</td>
<td>13<sup><xref ref-type="table-fn" rid="table-fn19-0194599812457557">c</xref></sup><break/>20<sup><xref ref-type="table-fn" rid="table-fn19-0194599812457557">c</xref></sup><break/>73<break/>80</td>
</tr>
<tr>
<td>Ariyasu et al (1990)<sup><xref ref-type="bibr" rid="bibr3-0194599812457557">3</xref></sup></td>
<td>n = 10<break/>Prednisone 23 mg/d, 1 d, tapering down 7 d</td>
<td>n = 10</td>
<td>1 mo</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>100</td>
<td>50</td>
</tr>
<tr>
<td>Strupp et al (2004)<sup><xref ref-type="bibr" rid="bibr5-0194599812457557">5</xref></sup></td>
<td>n = 35<break/>Prednisone 100 mg/d, 3 d, tapering down 19 d</td>
<td>n = 38</td>
<td>12 mo</td>
<td>78.7 (15.8)<sup><xref ref-type="table-fn" rid="table-fn19-0194599812457557">c</xref></sup></td>
<td>78.9 (24.0)</td>
<td>15.4 (16.2)<sup><xref ref-type="table-fn" rid="table-fn19-0194599812457557">c</xref></sup></td>
<td>39.0 (19.9)</td>
<td>23.6 (15.2 to 32.0)</td>
<td>63</td>
<td>21</td>
</tr>
<tr>
<td>Kitahara et al (2003)<sup><xref ref-type="bibr" rid="bibr6-0194599812457557">6</xref></sup></td>
<td>n = 18<break/>Prednisone 500 mg/d IV, 1 d, tapering down 7 d</td>
<td>n = 18</td>
<td>24 mo</td>
<td>90.5 (—)</td>
<td>68.1 (—)</td>
<td>18.3 (1.6)</td>
<td>12.5 (1.5)</td>
<td>−5.8 (−6.8 to −4.8)</td>
<td>72</td>
<td>56</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn17-0194599812457557">
<p>Unless otherwise indicated, the included data are presented as mean (SD). Abbreviations: CI, confidence interval; IV, intravenous; —, unknown.</p>
</fn>
<fn id="table-fn18-0194599812457557">
<label>a</label>
<p>The extent of unilateral caloric paresis at follow-up, expressed as improvement in mean caloric lateralization, was calculated using Jongkees’ formula<sup><xref ref-type="bibr" rid="bibr14-0194599812457557">14</xref></sup> in the studies performed by Shupak et al,<sup><xref ref-type="bibr" rid="bibr2-0194599812457557">2</xref></sup> Ariyasu et al,<sup><xref ref-type="bibr" rid="bibr3-0194599812457557">3</xref></sup> and Strupp et al.<sup><xref ref-type="bibr" rid="bibr5-0194599812457557">5</xref></sup> Kitahara et al<sup><xref ref-type="bibr" rid="bibr6-0194599812457557">6</xref></sup> measured the slow-phase eye velocity on the affected side only during caloric testing to determine the extent of vestibular paresis.</p>
</fn>
<fn id="table-fn19-0194599812457557">
<label>b</label>
<p>When between-group difference is positive, this favors corticosteroid or placebo.</p>
</fn>
<fn id="table-fn20-0194599812457557">
<label>c</label>
<p><italic>P</italic> &lt; .05.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Data on potential adverse effects of steroids were only systematically collected by Strupp et al.<sup><xref ref-type="bibr" rid="bibr5-0194599812457557">5</xref></sup> They reported side effects in 11 (19%) of 73 patients, varying from a peptic ulcer with bleeding to psychological side effects and hyperglycemia. All of the participants who reported side effects had received corticosteroids. No side effects were reported in the control group.</p>
</sec>
</sec>
<sec id="section8-0194599812457557">
<title>Translating Evidence into Practice</title>
<p>The available studies on the effect of corticosteroid treatment on early and late recovery of vestibular neuritis are rather small. Most provide indirect evidence or carry substantial risk of bias or both. They show small effects of corticosteroid treatment on symptom recovery and improved ENG test results at short-term follow-up. Little effect has been shown at longer term follow-up. Although studies reached statistical significance for some of their outcomes, we consider the reported effects of corticosteroid treatment too small to be clinically relevant.</p>
<p>In the interpretation of our findings, the following needs to be considered. First, apart from the study of Shupak et al,<sup><xref ref-type="bibr" rid="bibr2-0194599812457557">2</xref></sup> the risk of bias is rather high in all other studies. Although most studies included a placebo comparator, allocation was inadequately randomized and concealed, and outcome measurement was poorly blinded. Few studies adequately controlled for duration and severity of symptoms at entry, and there are large differences between studies in the size of the reported absolute effects after the placebo treatment. Furthermore, different types and dosages of comedication were used, and in one of the studies,<sup><xref ref-type="bibr" rid="bibr2-0194599812457557">2</xref></sup> comedication was restricted to the treatment group only.</p>
<p>Second, the sample size of studies was rather small, varying from 20 to 73 participants divided into 2 groups. In total, we were able to report on only 199 patients, which is a rather limited number of patients. Therefore, and because of multiple testing, we put little trust in the statistical significance of outcomes that studies reached. It is likely that these represent spurious results. Moreover, it should be noted that the difference in effects between treatments in general is rather small and does not always favor corticosteroids.</p>
<p>Third, the designs of the included studies largely differed in their approach to outcome measurement—notably, outcome measures and scales, timing, and duration of follow-up. This makes it difficult to compare their results. Therefore, the meaning of the size of reported effects is not clear, and the reported effects cannot simply be compared between studies. This and other major dissimilarities (eg, dosing of corticosteroid treatment) precluded pooling of study results. Only Shupak et al<sup><xref ref-type="bibr" rid="bibr2-0194599812457557">2</xref></sup> evaluated both short-term and long-term recovery.</p>
<p>Fourth, most studies relied on the caloric test results as the only outcome measure. However, despite improved ENG test results, Shupak et al<sup><xref ref-type="bibr" rid="bibr2-0194599812457557">2</xref></sup> and Kitahara et al<sup><xref ref-type="bibr" rid="bibr6-0194599812457557">6</xref></sup> show that compared with placebo, corticosteroid treatment has no effect on symptoms despite significant change in caloric test results. A previous report showed no correlation between ENG findings and residual clinical symptoms in a long-term follow-up of patients with vestibular neuritis.<sup><xref ref-type="bibr" rid="bibr11-0194599812457557">11</xref></sup> Therefore, we consider it not very likely that improvement in vestibular function as measured by ENG will translate in recovery from clinical signs and symptoms. It also remains to be shown whether earlier recovery from clinical signs and symptoms as reported translates in shorter hospital stay.</p>
</sec>
<sec id="section9-0194599812457557" sec-type="conclusions">
<title>Conclusion and Recommendation</title>
<p>The available studies on the effect of corticosteroid treatment on early and late recovery of vestibular neuritis carry a substantial high risk of bias. This precludes firm conclusions, and the reported short-term effects on symptom recovery and improvement of peripheral vestibular function (ENG test results) are too small to be considered clinically important. Corticosteroid treatment has little effect on outcomes at longer term follow-up.</p>
<p>Although studies reached statistical significance for some of their outcomes, we consider the effects of corticosteroid treatment too small to be clinically relevant. Taking into consideration the risk of adverse effects of steroid use, recommendations or decisions to treat patients with vestibular neuritis with corticosteroids cannot be based on current best evidence and, therefore, should be discussed with the patient.</p>
</sec>
<sec id="section10-0194599812457557">
<title>Author Contributions</title>
<p><bold>Inge Wegner</bold>, collected data, analyzed date, wrote article, final approval; <bold>Peter Paul G. van Benthem</bold>, designed study, revised article, final approval; <bold>Mark C. J. Aarts</bold>, analyzed data, revised article, final approval; <bold>Tjasse D. Bruintjes</bold>, designed study, revised article, final approval; <bold>Wilko Grolman</bold>, analyzed data, revised article, final approval; <bold>Geert J. M. G. van der Heijden</bold>, analyzed data, revised article, final approval.</p>
</sec>
<sec id="section11-0194599812457557">
<title>Disclosures</title>
<p><bold>Competing interests:</bold> None.</p>
<p><bold>Sponsorships:</bold> None.</p>
<p><bold>Funding source:</bold> None.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="presented-at">
<p>No sponsorships or competing interests have been disclosed for this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0194599812457557">
<label>1.</label>
<citation citation-type="web">
<collab>Biostat</collab>. <article-title>Comprehensive Meta-Analysis Version 2</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.meta-analysis.com">www.meta-analysis.com</ext-link></citation>
</ref>
<ref id="bibr2-0194599812457557">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shupak</surname><given-names>A</given-names></name>
<name><surname>Issa</surname><given-names>A</given-names></name>
<name><surname>Golz</surname><given-names>A</given-names></name>
<name><surname>Margalit</surname><given-names>K</given-names></name>
<name><surname>Braverman</surname><given-names>I</given-names></name>
</person-group>. <article-title>Prednisone treatment for vestibular neuritis</article-title>. <source>Otol Neurotol</source>. <year>2008</year>;<volume>29</volume>:<fpage>368</fpage>-<lpage>374</lpage>.</citation>
</ref>
<ref id="bibr3-0194599812457557">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ariyasu</surname><given-names>L</given-names></name>
<name><surname>Byl</surname><given-names>FM</given-names></name>
<name><surname>Sprague</surname><given-names>MS</given-names></name>
<name><surname>Adour</surname><given-names>KK</given-names></name>
</person-group>. <article-title>The beneficial effect of methylprednisolone in acute vestibular vertigo</article-title>. <source>Arch Otolaryngol Head Neck Surg</source>. <year>1990</year>;<volume>116</volume>:<fpage>700</fpage>-<lpage>703</lpage>.</citation>
</ref>
<ref id="bibr4-0194599812457557">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rezaie</surname><given-names>AA</given-names></name>
<name><surname>Hashemian</surname><given-names>F</given-names></name>
<name><surname>Rezaie</surname><given-names>N</given-names></name>
</person-group>. <article-title>Corticosteroids effect on vestibular neuritis symptom relief</article-title>. <source>Pak J Med Sci</source>. <year>2006</year>;<volume>22</volume>:<fpage>409</fpage>-<lpage>411</lpage>.</citation>
</ref>
<ref id="bibr5-0194599812457557">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Strupp</surname><given-names>M</given-names></name>
<name><surname>Zingler</surname><given-names>VC</given-names></name>
<name><surname>Arbusow</surname><given-names>V</given-names></name>
<name><surname>Niklas</surname><given-names>D</given-names></name>
<name><surname>Maag</surname><given-names>KP</given-names></name>
<name><surname>Dieterich</surname><given-names>M</given-names></name>
</person-group>. <article-title>Methylprednisolone, valacyclovir, or the combination for vestibular neuritis</article-title>. <source>N Engl J Med</source>. <year>2004</year>;<volume>22</volume>:<fpage>354</fpage>-<lpage>361</lpage>.</citation>
</ref>
<ref id="bibr6-0194599812457557">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kitahara</surname><given-names>T</given-names></name>
<name><surname>Kondoh</surname><given-names>K</given-names></name>
<name><surname>Morihana</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Steroid effects on vestibular compensation in human</article-title>. <source>Neurol Res</source>. <year>2003</year>;<volume>25</volume>:<fpage>287</fpage>-<lpage>291</lpage>.</citation>
</ref>
<ref id="bibr7-0194599812457557">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ohbayashi</surname><given-names>S</given-names></name>
<name><surname>Oda</surname><given-names>M</given-names></name>
<name><surname>Yamamoto</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Recovery of the vestibular function after vestibular neuronitis</article-title>. <source>Acta Otolaryngol Suppl</source>. <year>1993</year>;<volume>503</volume>:<fpage>31</fpage>-<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr8-0194599812457557">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Karlberg</surname><given-names>ML</given-names></name>
<name><surname>Magnusson</surname><given-names>M</given-names></name>
</person-group>. <article-title>Treatment of acute vestibular neuronitis with glucocorticoids</article-title>. <source>Otol Neurotol</source>. <year>2011</year>;<volume>32</volume>:<fpage>1140</fpage>-<lpage>1143</lpage>.</citation>
</ref>
<ref id="bibr9-0194599812457557">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yacovino</surname><given-names>DA</given-names></name>
<name><surname>Barreiro</surname><given-names>MA</given-names></name>
<name><surname>Rango</surname><given-names>G</given-names></name>
<name><surname>Sacheri</surname><given-names>C</given-names></name>
<name><surname>Gualtieri</surname><given-names>FJ</given-names></name>
</person-group>. <article-title>Vestibular neuritis: effect of prednisone on functional recovery</article-title>. <source>Neurol Argent</source>. <year>2010</year>;<volume>2</volume>:<fpage>149</fpage>-<lpage>154</lpage>.</citation>
</ref>
<ref id="bibr10-0194599812457557">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kitahara</surname><given-names>T</given-names></name>
<name><surname>Okumura</surname><given-names>S</given-names></name>
<name><surname>Takeda</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Effects of steroid therapy on long-term canal prognosis and activity in the daily life of vestibular neuronitis patients [in Japanese]</article-title>. <source>Nihon Jibiinkoka Gakkai Kaiho</source>. <year>2001</year>;<volume>104</volume>:<fpage>1059</fpage>-<lpage>1064</lpage>.</citation>
</ref>
<ref id="bibr11-0194599812457557">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bergenius</surname><given-names>J</given-names></name>
<name><surname>Perols</surname><given-names>O</given-names></name>
</person-group>. <article-title>Vestibular neuritis: a follow-up study</article-title>. <source>Acta Otolaryngol</source>. <year>1999</year>;<volume>119</volume>:<fpage>895</fpage>-<lpage>899</lpage>.</citation>
</ref>
<ref id="bibr12-0194599812457557">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jacobson</surname><given-names>GP</given-names></name>
<name><surname>Newman</surname><given-names>CW</given-names></name>
</person-group>. <article-title>The development of the Dizziness Handicap Inventory</article-title>. <source>Arch Otolaryngol Head Neck Surg</source>. <year>1990</year>;<volume>116</volume>:<fpage>424</fpage>-<lpage>427</lpage>.</citation>
</ref>
<ref id="bibr13-0194599812457557">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nishiike</surname><given-names>S</given-names></name>
<name><surname>Takeda</surname><given-names>N</given-names></name>
<name><surname>Koizuka</surname><given-names>I</given-names></name>
<name><surname>Hayashi</surname><given-names>H</given-names></name>
<name><surname>Kubo</surname><given-names>T</given-names></name>
<name><surname>Ogino</surname><given-names>H</given-names></name>
</person-group>. <article-title>Multivariate analysis of everyday handicap of patients with dizziness [in Japanese]</article-title>. <source>Nihon Jibiinkoka Gakkai Kaiho</source>. <year>1995</year>;<volume>98</volume>:<fpage>31</fpage>-<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr14-0194599812457557">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fife</surname><given-names>TD</given-names></name>
<name><surname>Tusa</surname><given-names>RJ</given-names></name>
<name><surname>Furman</surname><given-names>JM</given-names></name>
<etal/>
</person-group>. <article-title>Assessment: vestibular testing techniques in adults and children: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology</article-title>. <source>Neurology</source>. <year>2000</year>;<volume>55</volume>:<fpage>1431</fpage>-<lpage>1441</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>